Mitsunori Ushigome1, Yoshihiro Nabeya2, Hiroaki Soda2, Nobuhiro Takiguchi2, Akiko Kuwajima3, Masatoshi Tagawa4, Kazuyuki Matsushita5, Junichi Koike1, Kimihiko Funahashi1, Hideaki Shimada6. 1. Department of Surgery, School of Medicine, Toho University, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan. 2. Division of Gastroenterological Surgery, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba, 260-8717, Japan. 3. Medical & Biological Laboratories Co., Ltd, 4-5-3 Sakae, Naka-ku, Nagoya, 460-0008, Japan. 4. Division of Pathology and Cell Therapy, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba, 260-8717, Japan. 5. Department of Laboratory Medicine and Division of Clinical Genetics and Proteomics, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. 6. Department of Surgery, School of Medicine, Toho University, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan. hideaki.shimada@med.toho-u.ac.jp.
Abstract
BACKGROUND: Although serum p53 autoantibodies (s-p53-Abs) are induced even in the early stages of colorectal cancer, their positive rate is only approximately 20%. Therefore, we assessed the possibility of using other serum autoantibodies to increase the positive rates for detecting colorectal cancer. METHODS: Autoantibodies against 17 tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, NY-ESO-1, p90, Sui1, HSP40, CyclinB1, HCC-22-5, c-myc, PrxVI, VEGF, HCA25a, p62, and Annexin II) were evaluated in 279 patients with colorectal cancer and 74 healthy controls. Cutoff values were fixed at mean + 3 standard deviations of serum titers in healthy controls. RESULTS: Autoantibodies with the highest positive rates were p53 (20%), RalA (14%), HSP70 (12%), and Galectin1 (11%). Combination assays using multiple autoantibodies increased the positive rates based on the number of autoantibodies used. Positive rates of 56, 62, 66, 71, and 73% were obtained with 6, 9, 11, 14, and 17 antibodies, respectively, for the overall disease. Moreover, these autoantibodies showed relatively high positive rates even during stage 0/I disease (55 and 70% with 6 and 17 antibodies, respectively). CONCLUSION: The measurement of set of 17 autoantibodies allowed autoantibody profiling in patients with colorectal cancer. The combination assay of six tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, and NY-ESO-1) achieved a positive rate of 56%. Such high positive rates will be helpful for detecting colorectal cancer regardless of tumor stages.
BACKGROUND: Although serum p53 autoantibodies (s-p53-Abs) are induced even in the early stages of colorectal cancer, their positive rate is only approximately 20%. Therefore, we assessed the possibility of using other serum autoantibodies to increase the positive rates for detecting colorectal cancer. METHODS: Autoantibodies against 17 tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, NY-ESO-1, p90, Sui1, HSP40, CyclinB1, HCC-22-5, c-myc, PrxVI, VEGF, HCA25a, p62, and Annexin II) were evaluated in 279 patients with colorectal cancer and 74 healthy controls. Cutoff values were fixed at mean + 3 standard deviations of serum titers in healthy controls. RESULTS: Autoantibodies with the highest positive rates were p53 (20%), RalA (14%), HSP70 (12%), and Galectin1 (11%). Combination assays using multiple autoantibodies increased the positive rates based on the number of autoantibodies used. Positive rates of 56, 62, 66, 71, and 73% were obtained with 6, 9, 11, 14, and 17 antibodies, respectively, for the overall disease. Moreover, these autoantibodies showed relatively high positive rates even during stage 0/I disease (55 and 70% with 6 and 17 antibodies, respectively). CONCLUSION: The measurement of set of 17 autoantibodies allowed autoantibody profiling in patients with colorectal cancer. The combination assay of six tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, and NY-ESO-1) achieved a positive rate of 56%. Such high positive rates will be helpful for detecting colorectal cancer regardless of tumor stages.
Authors: Jian-Ying Zhang; Carlos A Casiano; Xuan-Xian Peng; James A Koziol; Edward K L Chan; Eng M Tan Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-02 Impact factor: 4.254
Authors: G E Trivers; V M De Benedetti; H L Cawley; G Caron; A M Harrington; W P Bennett; J R Jett; T V Colby; H Tazelaar; P Pairolero; R D Miller; C C Harris Journal: Clin Cancer Res Date: 1996-10 Impact factor: 12.531
Authors: P Boyle; C J Chapman; S Holdenrieder; A Murray; C Robertson; W C Wood; P Maddison; G Healey; G H Fairley; A C Barnes; J F R Robertson Journal: Ann Oncol Date: 2010-07-30 Impact factor: 32.976
Authors: H Shimada; T Hoshino; S Okazumi; H Matsubara; Y Funami; Y Nabeya; H Hayashi; A Takeda; T Shiratori; T Uno; H Ito; T Ochiai Journal: Br J Cancer Date: 2002-02-12 Impact factor: 7.640
Authors: Niall Brindl; Henning Boekhoff; Andrea S Bauer; Matthias M Gaida; Hien T Dang; Jörg Kaiser; Jörg D Hoheisel; Klaus Felix Journal: Cancers (Basel) Date: 2022-07-22 Impact factor: 6.575
Authors: Alistair Noble; Edward T Pring; Lydia Durant; Ripple Man; Stella M Dilke; Lesley Hoyles; Steve A James; Simon R Carding; John T Jenkins; Stella C Knight Journal: Cancer Immunol Immunother Date: 2022-03-22 Impact factor: 6.630